Antiretrovirals Linked to Risk of Kidney Disease
A recent study shows that HIV patients taking certain antiretrovirals could be at an increased risk for kidney disease.
About the Antiretroviral Study
Dr. Lene Ryom of the University Hospital of Copenhagen, Denmark and colleagues conducted the study and it shows that patients with HIV taking tenofovir, ritonavir-boosted atazanavir, or ritonavir-enhanced lopinavir could be at more of a risk for kidney disease with time.
According to Medscape, the study was conducted over five years. Ryom presented the results of the study at Conference on Retroviruses and Opportunistic Infections 2015. Results show that of the 23,560 participants in the study, over an average follow-up of 6.3 years, there were 210 cases of chronic kidney disease reported.
Ryom reported in the study that after done being treated with one of the antiretrovirals,tenofovir, the incidence rate ratio declined over time. The study does show that even after 2 years of not using the drug, the rate was still higher in those patients than in those never exposed to tenofovir.
Statistics Found by Dr. Ryom:
Incidence Rate Ratios for Chronic Kidney Disease:
- Tenofovir saw a kidney disease incident rate of 1.12 at one year of treatment, 1.25 at two years of treatment, and 1.74 at three years of treatment.
- Ritonavir-boosted atazanavir saw a kidney disease incident rate of 1.27 at one year of treatment, 1.61 at two years of treatment, and 3.27 at three years of treatment.
- Ritonavir-enhanced lopinavir saw a kidney disease incident rate of 1.16 at one year of treatment, 1.35 at two years of treatment, and 2.11 at three years of treatment.